ALK and non-small cell lung carcinoma: Other targeted therapy drugs that have been used in combination with chemotherapy for NSCLC include erlotinib, gefitinib, and afatinib for patients with EGFR mutations, and crizotinib, ceritinib, and alectinib for patients with ALK rearrangements.